Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma

Maris, 2007, Neuroblastoma, Lancet, 369, 2106, 10.1016/S0140-6736(07)60983-0 Pinto, 2015, Advances in risk classification and treatment strategies for neuroblastoma, J. Clin. Oncol., 33, 3008, 10.1200/JCO.2014.59.4648 Shimada, 2019, 1 Irwin, 2021, Revised neuroblastoma risk classification system: a report from the children's oncology group, J. Clin. Oncol., 39, 3229, 10.1200/JCO.21.00278 Bachmann, 2018, Polyamine synthesis as a target of MYC oncogenes, J. Biol. Chem., 293, 18757, 10.1074/jbc.TM118.003336 Pizzo, 2016 Otte, 2020, MYCN function in neuroblastoma development, Front. Oncol., 10 Gupta, 2018, Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells, Oncotarget, 9, 9907, 10.18632/oncotarget.24035 Amente, 2015, Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma, Oncotarget, 6, 14572, 10.18632/oncotarget.3990 Ambrosio, 2017, LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene, Oncotarget, 8, 3854, 10.18632/oncotarget.12924 Schulte, 2009, Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy, Cancer Res., 69, 2065, 10.1158/0008-5472.CAN-08-1735 Urban-Wojciuk, 2022, The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme, Cancer Gene Ther., 29, 940, 10.1038/s41417-021-00386-6 Holshouser, 2020, Epigenetic reexpression of hemoglobin F using reversible LSD1 inhibitors: potential therapies for sickle cell disease, ACS Omega, 5, 14750, 10.1021/acsomega.0c01585 Joshi, 2000, Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification), Pediatr. Dev. Pathol., 3, 184, 10.1007/s100240050024 Koppen, 2008, Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN, Int. J. Cancer, 122, 1455, 10.1002/ijc.23180 Shimada, 2001, International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group, Cancer, 92, 2451, 10.1002/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S Liu, 2020, Targeting MYCN in pediatric and adult cancers, Front. Oncol., 10 Sacilotto, 2021, Comprehensive in vitro characterization of the LSD1 small molecule inhibitor class in oncology, ACS Pharmacol. Transl. Sci., 4, 1818, 10.1021/acsptsci.1c00223 Dai, 2021, Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1, J. Med. Chem., 64, 2466, 10.1021/acs.jmedchem.0c02176 Sun, 2008, In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity, Chem. Res. Toxicol., 21, 711, 10.1021/tx7003085 Zhuo, 2018, Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors, Xenobiotica, 48, 1215, 10.1080/00498254.2017.1409915 Holshouser, 2019, Dual inhibitors of LSD1 and spermine oxidase, MedChemComm, 10, 778, 10.1039/C8MD00610E Kutz, 2014, 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors, MedChemComm, 5, 1863, 10.1039/C4MD00283K Kanouni, 2020, Discovery of CC-90011: a potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1), J. Med. Chem., 63, 14522, 10.1021/acs.jmedchem.0c00978 Hollebecque, 2022, Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies, Cancer, 128, 3185, 10.1002/cncr.34366 Menna, 2022, Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models, Eur. J. Med. Chem., 237, 10.1016/j.ejmech.2022.114410 Song, 2022, Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021, Eur. J. Med. Chem., 228, 10.1016/j.ejmech.2021.114042 Huang, 2007, Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes, Proc. Natl. Acad. Sci. U S A, 104, 8023, 10.1073/pnas.0700720104 Huang, 2009, Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes, Clin. Cancer Res., 15, 7217, 10.1158/1078-0432.CCR-09-1293 Nowotarski, 2015, Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures, Bioorg. Med. Chem., 23, 1601, 10.1016/j.bmc.2015.01.049 Sharma, 2010, (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators, J. Med. Chem., 53, 5197, 10.1021/jm100217a Sharma, 2012, Polyamine-based small molecule epigenetic modulators, Medchemcomm, 3, 14, 10.1039/C1MD00220A Hazeldine, 2012, Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1, J. Med. Chem., 55, 7378, 10.1021/jm3002845 Binda, 2010, Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2, J. Am. Chem. Soc., 132, 6827, 10.1021/ja101557k Tanimoto, 2020, Elimination of MYCN-amplified neuroblastoma cells by telomerase-targeted oncolytic virus via MYCN suppression, Mol. Ther. Oncolytics, 18, 14, 10.1016/j.omto.2020.05.015 Edsjo, 2004, Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation, Lab. Invest., 84, 406, 10.1038/labinvest.3700061 Zaatiti, 2018, Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration, Int. J. Oncol., 52, 787 Krstic, 2021, A chemo-genomic approach identifies diverse epigenetic therapeutic vulnerabilities in MYCN-amplified neuroblastoma, Front. Cell Dev. Biol., 9, 10.3389/fcell.2021.612518 Wang, 2019, FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma, Oncogene, 38, 6737, 10.1038/s41388-019-0912-5 Cheung, 2021, A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma, Oncogene, 40, 2367, 10.1038/s41388-021-01712-w Huang, 2017, Predicting drug combination index and simulating the network-regulation dynamics by mathematical modeling of drug-targeted EGFR-ERK signaling pathway, Sci. Rep., 7 Tallarida, 2011, Quantitative methods for assessing drug synergism, Genes Cancer, 2, 1003, 10.1177/1947601912440575 Dedoni, 2022, Upregulation of p75NTR by histone deacetylase inhibitors sensitizes human neuroblastoma cells to targeted immunotoxin-induced apoptosis, Int. J. Mol. Sci., 23, 10.3390/ijms23073849 Kaneda, 2022, The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity, Pediatr. Int., 64, 10.1111/ped.15159 Paul Gleeson, 2015, CHAPTER 1. Physicochemical properties and compound quality, 1